Clinical outcome assessments of motor status in patients undergoing brain tumor surgery

2021 ◽  
Vol 201 ◽  
pp. 106420
Author(s):  
Mayla Santana Correia ◽  
Iuri Santana Neville ◽  
Cesar Cimonari de Almeida ◽  
Cintya Yukie Hayashi ◽  
Luana Talita Diniz Ferreira ◽  
...  
2018 ◽  
Vol 6 (2) ◽  
pp. 81-92 ◽  
Author(s):  
Emanuela Molinari ◽  
Tito R Mendoza ◽  
Mark R Gilbert

Abstract Regulatory agencies have progressively emphasized the importance of assessing broader aspects of patient well-being to better define therapeutic gain. As a result, clinical outcome assessments (COAs) are increasingly used to evaluate the impact, both positive and negative, of cancer treatments and in some instances have played a major factor in the regulatory approval of drugs. Challenges remain, however, in the routine incorporation of these measures in cancer clinical trials, particularly in brain tumor studies. Factors unique to brain tumor patients such as cognitive decline and language dysfunction may hamper their successful implementation. Study designs often relegated these outcome measures to exploratory endpoints, further compromising data completion. New strategies are needed to maximize the complementary information that COAs could add to clinical trials alongside more traditional measures such as progression-free and overall survival. The routine incorporation of COAs as either primary or secondary objectives with attention to minimizing missing data should define a novel clinical trial design. We provide a review of the approaches, challenges, and opportunities for incorporating COAs into brain tumor clinical research, providing a perspective for integrating these measures into clinical trials.


2012 ◽  
Vol 108 (2) ◽  
pp. 327-332 ◽  
Author(s):  
A. Talacchi ◽  
D. d’Avella ◽  
L. Denaro ◽  
B. Santini ◽  
P. Meneghelli ◽  
...  

2018 ◽  
Author(s):  
C.H.B. van Niftrik ◽  
F. van der Wouden ◽  
V. Staartjes ◽  
J. Fierstra ◽  
M. Stienen ◽  
...  

2019 ◽  
Author(s):  
Estela Val Jordan ◽  
Agustín Nebra Puertas ◽  
Juan Casado Pellejero ◽  
Maria Dolores Vicente Gordo ◽  
Concepción Revilla López ◽  
...  

Author(s):  
Gennadiy A. Katsevman ◽  
Walter Greenleaf ◽  
Ricardo García-García ◽  
Maria Victoria Perea ◽  
Valentina Ladera ◽  
...  

2020 ◽  
Vol 2 (Supplement_3) ◽  
pp. ii2-ii2
Author(s):  
Tatsuya Abe

Abstract It is reported that the development of new perioperative motor deficits was associated with decreased overall survival despite similar extent of resection and adjuvant therapy. The maximum safe resection without any neurological deficits is required to improve overall survival in patients with brain tumor. Surgery is performed with various modalities, such as neuro-monitoring, photodynamic diagnosis, neuro-navigation, awake craniotomy, intraoperative MRI, and so on. Above all, awake craniotomy technique is now the standard procedure to achieve the maximum safe resection in patients with brain tumor. It is well known that before any treatment, gliomas generate globally (and not only focally) altered functional connectomics profiles, with various patterns of neural reorganization allowing different levels of cognitive compensation. Therefore, perioperative cortical mapping and elucidation of functional network, neuroplasticity and reorganization are important for brain tumor surgery. On the other hand, recent studies have proposed several gene signatures as biomarkers for different grades of gliomas from various perspectives. Then, we aimed to identify these biomarkers in pre-operative and/or intra-operative periods, using liquid biopsy, immunostaining and various PCR methods including rapid genotyping assay. In this presentation, we would like to demonstrate our surgical strategy based on molecular and functional connectomics profiles.


Sign in / Sign up

Export Citation Format

Share Document